M&A Deal Summary

Pfizer Acquires Hospira

On February 5, 2015, Pfizer acquired life science company Hospira for 17.0B USD

Acquisition Highlights
  • This is Pfizer’s 21st transaction in the Life Science sector.
  • This is Pfizer’s 5th largest (disclosed) transaction.
  • This is Pfizer’s 19th transaction in the United States.
  • This is Pfizer’s 1st transaction in Illinois.

M&A Deal Summary
Date 2015-02-05
Target Hospira
Sector Life Science
Buyer(s) Pfizer
Deal Type Add-on Acquisition
Deal Value 17.0B USD
Advisor(s) Morgan Stanley (Financial)
Skadden, Arps, Slate, Meagher & Flom (Legal)

Target

Hospira

Lake Forest, Illinois, United States
Hospira, Inc. is a global specialty pharmaceutical and medication delivery company dedicated to Advancing Wellness(TM). As the world leader in specialty generic injectable pharmaceuticals, Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. Through its products, Hospira helps improve the safety, cost and productivity of patient care. Hospira, Inc. is based in Lake Forest, Illinois.

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pfizer

New York, New York, United States
Category Company
Founded 1849
Sector Life Science
Employees8,300
Revenue 58.5B USD (2023)
DESCRIPTION
Pfizer office in Lake Forest, Illinois.
Pfizer office in Lake Forest, Illinois.

Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.

DEAL STATS #
Overall 24 of 43
Sector (Life Science) 21 of 39
Type (Add-on Acquisition) 19 of 31
State (Illinois) 1 of 1
Country (United States) 19 of 31
Year (2015) 2 of 3
Size (of disclosed) 5 of 21
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2015-01-07 Redvax

Zurich, Switzerland

Redvax is a Swiss, preclinical biopharmaceutical company based in Zurich. Redvax has produced a preclinical human cytomegalovirus (CMV) vaccine candidate, as well as intellectual property and a technology platform related to a second, undisclosed vaccine program.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-07-02 Pfizer - Ion Channel and Transporter Drug R&D

United States

Pfizer - Ion Channel and Transporter Drug R&D platform is a provider of comprehensive services for ion channel and transporter drug discovery, combining Icagen's industry-leading scientific expertise and extensive portfolio of assays and cell lines with XRpro Sciences' proprietary, label-free X-ray fluorescence technology.

Sell -
Mergr

Product

Company

Legal